When we use androgen deprivation therapy, we are lowering testosterone levels typically by turning off the testes from making testosterone. This starves cancer cells, causing them to shut down, ...

So when my urologist said in 2019 that my PSA test showed the most aggressive form of prostate cancer, I was not prepared. I was 68, and my annual tests had always been normal. Soon I embarked on a ...

Therapeutic Rationale Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of serious mental health risks.

Androgen deprivation therapy is commonly used to treat prostate cancer, often on an open-ended basis for therapy of advanced prostate cancer. It is estimated that 44 percent of men with prostate ...

Androgen deprivation therapy (ADT) for prostate cancer is associated with decreased bone mineral density (BMD) in patients. This decreased BMD can lead to an increased risk of fractures and ...

Androgen deprivation therapy (ADT) becomes less effective over time, but additional therapies like androgen receptor blockers and androgen synthesis inhibitors may extend life and improve the ...

Prostate cancer ranks high among male mortality causes worldwide. In this article, Sandy Srinivas, MD, discusses androgen deprivation therapy as a treatment for advanced prostate cancer and ...

I am Sandy Srinivas and I'm the host of the Medscape InDiscussion podcast series on prostate cancer. Today we want to talk about bone health and survivorship with androgen deprivation therapy (ADT).

Androgen deprivation therapy is a proven treatment for prostate cancer, but it can trigger biochemical events that might cause the cancer to progress to androgen-independent disease. This Review ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...